Pharmacological approach to diabetic macular edema

Ophthalmic Research

Volumn 51, Issue 2, 2014, Pages 88-95

  Bandello, F ^a   Casalino, G ^a   Loewenstein, A ^b   Goldstein, M ^b   Pelayes, D ^c   Battaglia Parodi, M ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b TEL AVIV UNIVERSITY   (Israel)

^c DEPARTAMENTO DE CIENCIAS NATURALES Y ANTROPOLOGÍA   (Argentina)

Author keywords

Anti vascular endothelial growth factor; Corticosteroids; Diabetic macular edema

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; BEVASIRANIB; CORTICOSTEROID; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; PEGAPTANIB; PF 04523655; RANIBIZUMAB; RAPAMYCIN; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

DIABETIC MACULAR EDEMA; DRUG DELIVERY SYSTEM; HUMAN; LOW LEVEL LASER THERAPY; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETINA MACULA EDEMA; REVIEW; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT; DRUG THERAPY; INTERMETHOD COMPARISON; LASER COAGULATION; SUSTAINED DRUG RELEASE;

ANGIOGENESIS INHIBITORS; COMBINED MODALITY THERAPY; DELAYED-ACTION PREPARATIONS; DIABETIC RETINOPATHY; DRUG IMPLANTS; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84893092486     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000356693     Document Type: Review

References (66)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977-986.
2. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854-865.
3. Early Treatment Diabetic Retinopathy Study research group: Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report No 1. Arch Oph-thalmol 1985; 103:1796-1806.
4. Lee CM, Olk RJ: Modified grid laser photoco-agulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology 1991; 98:1594-1602.
5. Bandello F, Battaglia Parodi M, Lanzetta P, Loewenstein A, Massin P, Menchini F, et al: Diabetic macular edema. Dev Ophthalmol 2010; 47:73-110.
6. Antonetti DA, Wolpert EB, DeMaio L, Harhaj NS, Scaduto RC Jr: Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neu-rochem 2002; 80:667-677. (Pubitemid 34809975)
7. Wang J, Xu X, Elliott MH, Zhu M, Le YZ: Muller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage. Diabetes 2010; 59:2297-2305.
8. Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, et al: Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009; 127:245-251.
9. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, et al: Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117:1064-1077.
10. Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, Friedman SM, et al: Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118:609-614.
11. Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, et al: Long-term benefit of sustained-delivery fluocinolone ace-tonide vitreous inserts for diabetic macular edema. Ophthalmology 2011; 118:626-635.
12. Lee SS, Hughes PM, Robinson MR: Recent advances in drug delivery systems for treating ocular complications of systemic diseases. Curr Opin Ophthalmol 2009; 20:511-519.
13. Audren F, Erginay A, Haouchine B, Benos-man R, Conrath J, Bergmann JF, et al: Intra-vitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthal-mol Scand 2006; 84:624-630. (Pubitemid 44317541)
14. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M: Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006; 113:1533-1558.
15. Jonas JB, Kamppeter BA, Harder B, Vossmer-baeumer U, Sauder G, Spandau UH: Intravit-real triamcinolone acetonide for diabetic mac-ular edema: a prospective, randomized study. J Ocul Pharmacol Ther 2006; 22:200-207. (Pubitemid 44051133)
16. Jonas JB: Intravitreal triamcinolone aceton-ide: a change in a paradigm. Ophthalmic Res 2006; 38:218-245. (Pubitemid 44213982)
17. Gillies MC, Simpson JM, Gaston C, Hunt G, Ali H, Zhu M, et al: Five-year results of a randomized trial with open-label extension of tri-amcinolone acetonide for refractory diabetic macular edema. Ophthalmology 2009; 116: 2182-2187.
18. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid pho-tocoagulation for diabetic macular edema. Ophthalmology 2008; 115:1447-1449. e1-e10.
19. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S: Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009; 116:73-79.
20. Haller JA, Dugel P, Weinberg DV, Chou C, Whitcup SM: Evaluation of the safety and performance of an applicator for a novel in-travitreal dexamethasone drug delivery system for the treatment of macular edema. Retina 2009; 29:46-51.
21. Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, et al: Pharmacokinetics and pharmaco-dynamics of a sustained-release dexametha-sone intravitreal implant. Invest Ophthalmol Vis Sci 2011; 52:80-86.
22. Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, et al: Randomized controlled trial of an intravit-reous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010; 128:289-296.
23. Zucchiatti I, Lattanzio R, Querques G, Quer-ques L, Del Turco C, Cascavilla ML, et al: In-travitreal dexamethasone implant in patients with persistent diabetic macular edema. Oph-thalmologica 2012; 228:117-122.
24. Boyer DS, Faber D, Gupta S, Patel SS, Taban-deh H, Li XY, et al: Dexamethasone intravit-real implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011; 31:915-923.
25. Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, et al: Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012; 119:2125-2132.
26. Pearson PA, Comstock TL, Ip M, Callanan D, Morse LS, Ashton P, et al: Fluocinolone ace-tonide intravitreal implant for diabetic macu-lar edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011; 118:1580-1587.
27. Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J, et al: Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142:961-969.
28. Iacono P, Battaglia Parodi M, Bandello F: An-tivascular endothelial growth factor in diabetic retinopathy. Dev Ophthalmol 2010; 46:39-53.
29. Bandello F, Berchicci L, La Spina C, Battaglia Parodi M, Iacono P: Evidence for anti-VEGF treatment of diabetic macular edema. Ophthalmic Res 2012; 48(suppl 1):16-20.
30. Ferrara N, Damico L, Shams N, Lowman H, Kim R: Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26:859-870. (Pubitemid 44547437)
31. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al: Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33:2399-2405.
32. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al: Primary end point (six months) results of the Ranibizumab for Edema of the Macula in Diabetes (READ-2) study. Ophthalmology 2009; 116:2175-2181.
33. Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, et al: Two-year outcomes of the Ranibizumab for Edema of the Macula in Diabetes (READ-2) study. Ophthalmology 2010; 117:2146-2151.
34. Do DV, Nguyen QD, Khwaja AA, Channa R, Sepah YJ, Sophie R, et al: Ranibizumab for Edema of the Macula in Diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol 2013; 131:139-145.
35. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al: The RESTORE study: ranibizumab mono-therapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118:615-625.
36. Lang GE, Berta A, Eldem BM, Simader C, Sharp D, Holz FG, et al: Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology 2013; 120:2004-2012.
37. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al: Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119:789-801.
38. Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al: Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120:2013-2022.
39. Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, et al: Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic reti-nopathy in a randomized clinical trial. JAMA Ophthalmol 2013; 131:1033-1040.
40. Bandello F, Cunha-Vaz J, Chong NV, Lang GE, Massin P, Mitchell P, et al: New approaches for the treatment of diabetic macu-lar oedema: recommendations by an expert panel. Eye (Lond) 2012; 26:485-493.
41. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report No 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1987; 94:761-774.
42. Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, et al: A phase II randomized clinical trial of intravitreal beva-cizumab for diabetic macular edema. Ophthalmology 2007; 114:1860-1867.
43. Arevalo JF, Sanchez JG, Wu L, Maia M, Alez-zandrini AA, Brito M, et al: Primary intravit-real bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 2009; 116:1488-1497.
44. Lam DS, Lai TY, Lee VY, Chan CK, Liu DT, Mohamed S, et al: Efficacy of 1.25 mg versus 2.5 mg intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. Retina 2009; 29:292-299.
45. Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, et al: Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. Retina 2008; 28:1053-1060.
46. Soheilian M, Ramezani A, Bijanzadeh B, Ya-seri M, Ahmadieh H, Dehghan MH, et al: In-travitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 2007; 27:1187-1195. (Pubitemid 350211523)
47. Soheilian M, Ramezani A, Obudi A, Bijanza-deh B, Salehipour M, Yaseri M, et al: Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009; 116:1142-1150.
48. Soheilian M, Garfami KH, Ramezani A, Ya-seri M, Peyman GA: Two-year results of a randomized trial of intravitreal bevacizu-mab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina 2012; 32:314-321.
49. Michaelides M, Kaines A, Hamilton RD, Fra-ser-Bell S, Rajendram R, Quhill F, et al: A prospective randomized trial of intravitreal beva-cizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010; 117:1078-1086.
50. Rajendram R, Fraser-Bell S, Kaines A, Mi-chaelides M, Hamilton RD, Esposti SD, et al: A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema 24-month data: report 3. Arch Ophthalmol 2012; 130:972-979.
51. Sivaprasad S, Crosby-Nwaobi R, Heng LZ, Peto T, Michaelides M, Hykin P: Injection frequency and response to bevacizumab mono-therapy for diabetic macular oedema (BOLT report 5). Br J Ophthalmol 2013; 97:1177-1180.
52. Goyal S, Lavalley M, Subramanian ML: Meta-analysis and review on the effect of bevaci-zumab in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2011; 249:15-27.
53. Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, et al: A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112:1747-1757.
54. Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS: A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011; 118:1107-1118.
55. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al: Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 2012; 119:2537-2548.
56. Do DV, Schmidt-Erfurth U, Gonzalez VH, Gordon CM, Tolentino M, Berliner AJ, et al: The Da Vinci Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 2011; 118: 1819-1826.
57. Do DV, Nguyen QD, Boyer D, Schmidt-Er-furth U, Brown DM, Vitti R, et al: One-year outcomes of the Da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012; 119:1658-1665.
58. Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, Ferris FL 3rd, et al: Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012; 119:2312-2318.
59. Bandello F, Battaglia Parodi M, Tremolada G, Lattanzio R, De Benedetto U, Iacono P: Steroids as part of combination treatment: the future for the management of macular edema? Ophthalmologica 2010; 224(suppl 1):41-45.
60. Gillies MC, McAllister IL, Zhu M, Wong W, Louis D, Arnold JJ, et al: Intravitreal triam-cinolone prior to laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial. Ophthalmology 2011; 118:866-872.
61. Lim JW, Lee HK, Shin MC: Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica 2012; 227:100-106.
62. Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD, et al: Dexa-methasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 2013; 120:1843-1851.
63. Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Basile AS, Klamerus KJ, et al: Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study). Invest Ophthalmol Vis Sci 2012; 53:7666-7674.
64. Prenner JL, RACE Study Group: The RACE Study: bevasiranib for the treatment of diabetic macular edema (abstract 5045). Assoc Res Vision Ophthalmol Annu Meet, Fort Lauderdale, October 5, 2007.
65. Krishnadev N, Forooghian F, Cukras C, Wong W, Saligan L, Chew EY, et al: Subcon-junctival sirolimus in the treatment of diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2011; 249:1627-1633.
66. Dugel PU, Blumenkranz MS, Haller JA, Williams GA, Solley WA, Kleinman DM, et al: A randomized, dose-escalation study of sub-conjunctival and intravitreal injections of si-rolimus in patients with diabetic macular edema. Ophthalmology 2012; 119:124-131.